The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Identification and Characterization of Compounds that Regulate the Activity of the LRRK2 System
Study Rationale: Genetic mutations that lead to the activation of the enzyme LRRK2 are a major cause of inherited Parkinson's disease (PD). We have identified a protein, termed PPM1H, that counteracts...
-
, 2022Fostering Inclusivity in Research Engagement for Underrepresented Populations in Parkinson’s Disease, Phase II (FIRE-UP PD II)
Study Rationale: In recent years, scientists have learned that improving representation of all people in clinical research is an important way to fully understand diseases. This also ensures that new...
-
Alpha-synuclein Seed Amplification Assay Program, 2022Quantifying Alpha-synuclein Aggregates Using Nanopore Sensor
Study Rationale: Parkinson’s disease (PD) is associated with an accumulation of alpha-synuclein aggregates in the brain; however, the current methods used to identify these aggregates in biological...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Targeting the Interaction of Alpha-synuclein with Lipids as a Therapeutic for Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is characterized by an abnormal accumulation of alpha-synuclein. One of this protein’s normal functions involves binding to fatty acids and lipids, and...
-
Fall 2021 RFP: Expanding Biological Understanding of PD, 2022Evaluation of Gene Products that Counteract the Action of LRRK2
Study Rationale: Although most cases of Parkinson’s disease (PD) are of unknown origin, some forms can be inherited. Mutations that activate the enzyme LRRK2 are a major cause of inherited PD, and...
-
Alpha-synuclein Seed Amplification Assay Program, 2021Detection of Single Molecules of Alpha-synuclein in Extracellular Vesicles
Study Rationale: The pathological changes observed in the brain tissue of people with Parkinson’s disease (PD) compared to healthy individuals motivated researchers to explore alpha-synuclein as a...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.